Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice.

He YG, Pappworth IY, Rossbach A, Paulin J, Mavimba T, Hayes C, Kulik L, Holers VM, Knight AM, Marchbank KJ.

Immunobiology. 2018 Jan;223(1):125-134. doi: 10.1016/j.imbio.2017.10.002. Epub 2017 Oct 4.

2.

C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.

Toapanta FR, DeAlmeida DR, Dunn MD, Ross TM.

Immunol Lett. 2010 Mar 10;129(1):32-8. doi: 10.1016/j.imlet.2009.12.022. Epub 2010 Jan 12.

3.

A minimum CR2 binding domain of C3d enhances immunity following vaccination.

Bower JF, Ross TM.

Adv Exp Med Biol. 2006;586:249-64.

PMID:
16893077
4.

Efficient production of complement (C3d)3 fusion proteins using the baculovirus expression vector system.

Barrault DV, Steward M, Cox VF, Smith RA, Knight AM.

J Immunol Methods. 2005 Sep;304(1-2):158-73.

PMID:
16109422
6.

Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.

Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM.

J Immunol. 2001 Nov 15;167(10):5758-66.

8.

Construction and immunogenicity of DNA vaccines encoding fusion protein of murine complement C3d-p28 and GP5 gene of porcine reproductive and respiratory syndrome virus.

Zhang D, Xia Q, Wu J, Liu D, Wang X, Niu Z.

Vaccine. 2011 Jan 17;29(4):629-35. doi: 10.1016/j.vaccine.2010.11.046. Epub 2010 Dec 4.

PMID:
21134449
9.

Contribution of Chinese Pekin duck complement component C3d-P29 repeats to enhancement of Th2-biased immune responses against NDV F gene induced by DNA immunization.

Liu D, Wang J, Niu ZX.

Immunopharmacol Immunotoxicol. 2010 Jun;32(2):297-306. doi: 10.3109/08923970903311802.

PMID:
20148704
10.
11.

Mouse strain-dependent differences in enhancement of immune responses by C3d.

Toapanta FR, Ross TM.

Vaccine. 2004 Apr 16;22(13-14):1773-81.

PMID:
15068861
12.
13.

Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression.

Haas KM, Toapanta FR, Oliver JA, Poe JC, Weis JH, Karp DR, Bower JF, Ross TM, Tedder TF.

J Immunol. 2004 May 15;172(10):5833-7.

14.

Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.

Lambris JD, Ganu VS, Hirani S, Müller-Eberhard HJ.

Proc Natl Acad Sci U S A. 1985 Jun;82(12):4235-9.

15.
16.

C3d of complement as a molecular adjuvant: bridging innate and acquired immunity.

Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT.

Science. 1996 Jan 19;271(5247):348-50.

PMID:
8553069
18.
19.

Novel function of complement C3d as an autologous helper T-cell target.

Knopf PM, Rivera DS, Hai SH, McMurry J, Martin W, De Groot AS.

Immunol Cell Biol. 2008 Mar-Apr;86(3):221-5. doi: 10.1038/sj.icb.7100147. Epub 2008 Jan 8.

PMID:
18180801
20.

C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells.

De Groot AS, Ross TM, Levitz L, Messitt TJ, Tassone R, Boyle CM, Vincelli AJ, Moise L, Martin W, Knopf PM.

Immunol Cell Biol. 2015 Feb;93(2):189-97. doi: 10.1038/icb.2014.89. Epub 2014 Nov 11.

Supplemental Content

Support Center